Pharma figures 2018 The (bio)pharmaceutical sector in Belgium: the beating heart of the knowledge economy
KEY FIGURES 2018
Jobs
R & D investments
Exports
37,073
3.6 billion €
42.9 billion €
(+3.8 %)
(+1.8 %)
Researchers
Clinical trials
5,295
n° 2 in Europe relative to population size
(+3.9 %)
2
(+6.2 %)
The (bio)pharmaceutical sector in Belgium: the beating heart of the knowledge economy In 2018, innovative (bio)pharmaceutical companies strengthened their position in Belgium yet again. The figures you will see in this brochure are a testimony to the vitality of our industry and the substantial contribution it makes to the Belgian economy. Employment in (bio)pharmaceuticals rose by almost 10% from 2014 to 2018. Over the last five years, R&D spending by (bio)pharma compagnies has risen by 40.6%. 2018 was another record year: the number of jobs rose 3.8% to reach 37,073, the number of researchers in our businesses rose to 5,295, R&D spending rose to some ₏3.6 billion, and exports of medicines and vaccines were almost ₏43 billion – all factors that go to show how the biopharmaceutical companies belong to the beating heart of the Belgian knowledge economy. Catherine Rutten CEO pharma.be
3
JOBS THE PHARMA INDUSTRY: SPURRING EMPLOYMENT GROWTH IN BELGIUM 1 37,073 people work in the (bio)pharmaceutical sector in Belgium. In five years time, the total number of jobs created in the industry has risen by almost 10%, and that’s without counting indirect employment. Today, the (bio)pharmaceutical industry accounts for 7.8% of total manufacturing employment.
DID YOU KNOW? In five years, the total number of jobs created in the industry has risen by almost 10%.
GROWTH RATE IN 2018 RELATIVE TO 2017
3.8%
37 ,
(+ 07 3. 3 8 % )
35
(+ ,71 1. 1 3 % )
35
(+ ,25 1. 6 0 % )
34
(+ ,69 1. 8 8 % )
34
,0 75
EMPLOYMENT GROWTH IN THE (BIO)PHARMACEUTICAL INDUSTRY / NUMBER OF EMPLOYEES
1.6%
2018
1 Sources : ONSS, pharma.be
ct se
uf
an
Pr
iv
at
e
eu ac rm ha io )p (B
4
M
2017
s
2016
al
2015
tic
2014
or ac t in ur in du g st ry
1.1%
A RISING NUMBER OF RESEARCHERS 2 The (bio)pharmaceutical sector is also one of Belgium’s most innovative industries. In 2018, it attracted a large number of new researchers. In the biopharmaceutical companies in Belgium, 5,295 people work every day to develop innovative medicines and treatments.
DID YOU KNOW? Between 2014 and 2018, 1,173 researchers joined the (bio)pharmaceutical industry – a rise of over 28%
2014
2015
2016
2 Source : pharma.be member firms performing fundamental R&D
5,
2
(+ 95 3. 9 % )
5,
0
(+ 98 14 % )
) %
.6
47 2 4,
(+ 5
4,
2
(+ 37 2. 9 % )
4,
11 9
EVOLUTION OF THE NUMBERS OF PERSONS ACTIVE IN R&D
2017
2018
5
THE (BIO)PHARMACEUTICAL INDUSTRY IS AT THE HEART OF THE KNOWLEDGE ECONOMY 3 The fundamental raw material of the (bio)pharmaceutical industry is its ability to innovate. This constant innovation is nurtured by all 37,073 employees in the sector. Over two thirds of (bio) pharmaceutical employees hold a qualification from a higher educational institution.
65,8% of employees have a degree-level education or above
6
3 Source: Statistics Belgium, Labour Force Survey 2018
AN INDUSTRY THAT STRIVES FOR DIVERSITY 4 Women are active at every level of the (bio)pharmaceutical industry, whether in research and development, in logistics departments or in management positions. Among pharma.be member firms, 50% of employees are women, and this figure rises to 57% in R&D departments (labs, clinical trials, medical departments etc.). Furthermore, 46% of management positions in these Belgian-based firms are held by women and 29% of board members are female.
WOMEN REPRESENT:
50%
of employees
57%
in R&D departments
4 Survey of pharma.be members, February 2019
46%
of management positions
29%
of board members
7
RESEARCH & DEVELOPMENT RECORD INVESTMENT IN RESEARCH & DEVELOPMENT OF INNOVATIVE MEDICINES The (bio)pharmaceutical sector plays a central role in the discovery and production of new medicines. In 2018, (bio)pharmaceutical companies invested almost €3.6 billion 5 on research and development in Belgium – that is €10 million a day! This figure represents yet another rise in relation to 2017, which was already a record year in which investments passed the €3.5 billion mark for the first time.
R&D SPENDING BY BELGIAN (BIO)PHARMACEUTICAL BUSINESSES CARRYING OUT FUNDAMENTAL RESEARCH AIMED AT DEVELOPING MEDICINES FOR HUMAN USE
(IN BILLIONS OF €)
DID YOU KNOW? (Bio)pharmaceutical businesses based in Belgium invest nearly €10m a day on research and development.
3.51 2.54
2014
2.59
2015
3.57
2.89
2016
2017
2018
DID YOU KNOW? A new patent almost every two days for innovative medicines! With over 162 patent applications filed in Belgium in 2018 6 (up 30% in a year)
8
5 Source: pharma.be (from the database provided by pharma.be member firms) 6 Source: European Patent Office (EPO)
BELGIUM, AN ATTRACTIVE COUNTRY FOR CLINICAL TRIALS 7 Clinical trials are an essential phase in the development of innovative medicines. Fifty-two of the (bio) pharmaceutical companies belonging to pharma.be carry out clinical trials in Belgium. They include not only major companies but also a large number of small and medium-sized firms, many of them employing the very latest scientific techniques to create new cell and gene therapies.
NUMBER OF PHARMA.BE MEMBER FIRMS CARRYING OUT CLINICAL TRIALS IN BELGIUM
52
In Europe, Belgium ranks as the second most attractive country in which to run clinical trials. For patients, living in a country that attracts large numbers of clinical trials is an undeniable boon, as they have sooner access to innovative therapies. In Belgium, 77% of all clinical trials are organised and funded by (bio)pharmaceutical companies. This is one of the highest ratios of private funding in Europe. The remaining 23% are initiated by universities or the public sector.
23% Academic clinical trials
77%
Clinical trials initiated by the (bio)pharmaceutical sector
BELGIUM 2017
7 Source: Monitor Deloitte analyses based on EU Clinical Trials Register data; Denmark, Estonia, France, Germany, the Netherlands, Poland, Spain, Sweden, and the United Kingdom. 15 February 2019, data for 2017.
9
EXPORTS BELGIUM, A LEADING HUB FOR (BIO)PHARMACEUTICAL EXPORTS 8 2018 was another record-breaking year for exports of pharmaceuticals out of Belgium. The value of (bio)pharmaceutical products that were exported from Belgium all over the globe, totalled €42.9 billion in 2018, representing a growth rate of 6.2% over the previous year. Belgium is ideally located at the heart of the European Union, and benefits from a dense network of high-quality logistics infrastructure. In 2018 Belgium has consolidated its position as a leading centre for (bio)pharmaceutical exports.
DID YOU KNOW? In 2018, nearly €118 million of (bio) pharmaceutical products were exported from Belgium every day.
EXPORTS OF PHARMACEUTICAL PRODUCTS IN BILLIONS OF €
39.84 2014
10
41.01
2015
8 Source: National Bank of Belgium, EU methodology
40.73
2016
+6.2 40.36
2017
42.87
2018
BELGIUM EXPORTS (BIO)PHARMACEUTICAL PRODUCTS ACROSS THE GLOBE
6.
2.8% % 3. 4
1.6%
Belgium’s (bio)pharmaceutical companies have a resolutely global outlook. Nearly half (46%) of all pharmaceutical exports go to countries outside the European Union, primarily the United States. Within the EU, Germany is the main destination. Belgium is thus a global hub for the distribution of medicines and vaccines.
6%
12.2% BELGIAN EXPORTS OF PHARMACEUTICAL PRODUCTS IN 2018 BY REGION (% OF TOTAL)
53.7%
19.7% European Union
Rest of Europe
North America
Central & South America
Asia
Africa
11
The geographical distribution of (bio)pharmaceutical exports is unique in comparison to Belgium’s exports overall, which are predominantly intra-European.
BELGIAN (BIO)PHARMACEUTICAL EXPORTS BY DESTINATION (IN %)
46.3%
EU28
12
Outside EU
BELGIAN EXPORTS BY DESTINATION (IN %)
23% 53.7%
77%
TOP 5 DESTINATION COUNTRIES FOR BELGIAN PHARMACEUTICAL EXPORTS WITHIN EUROPEAN UNION
DID YOU KNOW?
Germany
France
United Kingdom
Italy
Spain
Japan
Russian Federation
Belgium was a net exporter of (bio) pharmaceutical products in 2018, achieving a positive balance of trade 9 of €6.8 billion.
OUTSIDE OF EUROPEAN UNION
United States
Canada
PR China
9 Sources: National Bank of Belgium, pharma.be calculations (The balance of trade is the difference between exports & imports of goods & services)
13
pharma.be, the General Association of the Innovative Medicines Industry, brings together more than 130 innovative (bio) pharmaceutical companies active in Belgium. These companies focus on research and development of new medicinal products for both human and veterinary use and employ more than 37,000 employees in Belgium.
Partner in health and innovation As a committed partner of physicians, pharmacists, hospitals, authorities and other health partners, pharma.be’s mission is to promote the best healthcare by promoting therapeutic innovation in the field of medicinal products for human use. Its top priority is therefore to allow patients the fastest possible access to the most recent treatments from research and development.
14
(BIO)PHARMACEUTICAL COMPANIES MEMBERS OF PHARMA.BE
130+
(Bio)pharmaceutical companies
37
Production sites
23
Headquarters in Belgium
52
R&D and Clinical R&D sites
15
FOLLOW THE PHARMA.BE COMMUNITY ON
Responsible editor : Catherine Rutten 166 Chaussée de La Hulpe, 1170 Brussels - Belgium Legal deposit: D/2019/4021/6